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PURPOSE:
Recent studies indicate that roughly 6% of opioid-naïve patients undergoing elective procedures develop new persistent opioid use. Body contouring is commonly performed to enhance quality of life and appearance, but opioid prescribing patterns among this population remain unknown.
METHODS:
We examined insurance claims from OptumInsight between 2001 and 2015 for opioid-naïve patients undergoing five common body contouring procedures: abdominoplasty/panniculectomy, breast reduction, mastopexy, brachioplasty, and thighplasty (n=17,894). Our primary outcome included new persistent opioid use, defined as prescription fills between 90 and 180 days after the operation. We used multilevel mixed-effects logistic regression to assess the risk of new persistent use, adjusting for clinical and sociodemographic covariates. PURPOSE: Deoxycholic acid is approved for minimally invasive treatment of submental fat. Safety profiles from pivotal studies did not report on the potential adverse effect of localized alopecia. Knowledge about any potential adverse event (AE), including alopecia, is important for informed consent and setting patient expectations. This study is the first to characterize alopecia in patients undergoing deoxycholic acid treatment for submental fat and the
RESULTS:

